Navigation Links
Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
Date:10/22/2007

07207en.pdf" target="_new">http://www.emea.europa.eu/pdfs/human/comp/29007207en.pdf

"These US and European Union incentives will allow Sequella to move SQ109 through the product development process more quickly and efficiently," said Dr. Nacy.

SQ 109 also received Fast Track Status from the FDA in January of 2007.

About Tuberculosis (TB)

TB is a contagious infectious disease caused by the bacterium Mycobacterium tuberculosis. TB bacteria can be inhaled into lungs and are able to avoid destruction by certain white blood cells. Without containment by immune cells, the bacteria can spread throughout the body, multiply, survive and remain dormant for years. TB is the leading cause of global deaths that result from a single-agent infectious disease.

About Sequella, Inc.

Sequella is a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, infectious disease expertise and diverse product portfolio to proactively address emerging health threats with significant market opportunity. For more information, please visit http://www.sequella.com.

Forward-Looking Statement

This press release contains forwardlooking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.


'/>"/>
SOURCE Sequella, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Isolation and Characterization of Anti-Viral Nucleoside Compounds from the Chinese Herb Taraxacum Mongolicum
2. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
3. UW compound counters Avian flu
4. Medical College receives $377K to study brain disease
5. Lucigen receives $750K grant to boost biofuel yields
6. Medical College receives $1.4M cancer grant
7. Wisconsin biotech firm receives $107K NIH grant
8. InvivoSciences receives NIH grant for heart technology
9. Medical College receives $11 million grant to study high blood pressure
10. Madison business receives $115,000 of new state biofuels funding
11. Superior receives funds for technical training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
(Date:8/26/2015)... SAN FRANCISCO , Aug. 26, 2015 /PRNewswire/ ... today that it has received a $1.5M Phase ... Health (NIH) to further develop its therapeutic agent ... unmet clinical need in end stage renal disease ... by the National Institute of Diabetes and Digestive ...
(Date:8/26/2015)... -- China Cord Blood Corporation (NYSE: CO ) ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has been informed that Magnum Opus 2 ... Mr. Yuen Kam, chairman of the board of directors ... "Shares") of  Excellent China Healthcare Investment Limited ("KKR SPV") ...
(Date:8/26/2015)... San Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... three major conferences to develop new business relationships with local sponsors in southern California. ... services to facilitate their drug development processes and regulatory pathways., , ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... S*BIO Pte Ltd today announced that,the U.S. ... drug,designation to SB1518, its potent and orally-active JAK2 ... FDA accepted S*BIO,s,application upon review of preclinical data ... very good,tolerability of the JAK2 inhibitor., "We ...
... 13 Johnson & Johnson today announced that,Professor ... Sir,Ravinder N. Maini, FRCP, FMedSci, FRS of the ... named the recipients of the,2008 Dr. Paul Janssen ... of world-renowned scientists., The award salutes the ...
... May 12 Meditor Pharmaceuticals Ltd.,announced today the appointment ... Advisor to the company., Dr. Schachner has been ... will now take a more active role in the ... Head of the Cardiac Surgery,Department at Wolfson Medical Center ...
Cached Biology Technology:S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders 2Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 2Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 3Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research 4Two New Appointments at Meditor Pharmaceuticals Ltd. 2
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... new extinct camel species by University of Florida scientists sheds ... containing more than half the world,s biodiversity and some of ... the Journal of Vertebrate Paleontology , the study is ... part of an international project in Panama. Funded with a ...
... While some scientists report engineering a super virulent strain of ... significant percentage of the human population, another group of researchers ... one day help mitigate the deadly effects of all flu ... of the Journal of Leukocyte Biology , ...
... will soon host its annual Spring Review from 5 ... be held at 950 Glebe Road, Suite 210, in ... assessment of AFOSR,s research portfolio. , Since its ... in extramural basic research programs at leading universities and ...
Cached Biology News:UF scientists name new ancient camels from Panama Canal excavation 2UF scientists name new ancient camels from Panama Canal excavation 3New light shed on cause of lung injury in severe flu 2